Clinical Trial: Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Anatomic Stage IV Breast Cancer AJCC v8
Study Type: INTERVENTIONAL
Official Title: Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFN?2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Neg
Brief Summary:
This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable).CKM drugs such as rintatolimod and interferon alpha 2b work to modify the immune response and…
Read more